Plain-English translation of NCT07362095 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a medication called to help treat anemia (low red blood cell counts) in patients who have received a stem cell transplant as treatment for acute leukemia. After transplant, many patients develop anemia, which can cause fatigue and other complications. Researchers want to see if this medication can safely help boost red blood cell production and reduce the need for blood transfusions.
After a stem cell transplant, patients often struggle with low red blood cell counts for weeks or months, which requires frequent blood transfusions and can be physically taxing. This trial aims to find out whether this medication could help the body make more red blood cells naturally, improving patient recovery and reducing dependence on transfusions.
You likely qualify if…
You likely don't qualify if…
You would receive two injections of the medication under your skin—one about a week after your transplant and another about a month after transplant. Over the first two months, you'll have frequent clinic visits for blood tests, vital signs checks, and physical exams to monitor how well the medication is working and watch for any side effects. The research team will also track whether you need fewer blood transfusions and how well your blood cells are recovering.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
China